Key Highlights

  • Liquidia (NASDAQ:LQDA) rose 7.37% on November 10, 2026 after third-quarter results showed Yutrepia net product sales of USD 222.7 million, up 31% from the second quarter.
  • The company reported a net loss of USD 236.3 million, or USD 2.64 per share, which included a USD 389.7 million litigation settlement charge and a USD 30.1 million tax benefit.
  • Adjusted EBITDA rose for a fifth straight quarter to USD 140.5 million, and cash stood at USD 396.1 million at September 30 before settlement payments.
  • The October settlement with United Therapeutics resolves all six pending lawsuits in exchange for net payments of USD 380.7 million across 2026 and 2027.

Why the Stock Rose on a Loss

The headline loss from Liquidia (NASDAQ:LQDA) looked severe, but investors focused on the operating Business and the end of years of litigation. Yutrepia, an inhaled dry-powder form of treprostinil for pulmonary arterial hypertension, generated USD 222.7 million of net sales in the quarter, compared with USD 51.7 million a year earlier, when the launch was only beginning. Sales grew 31% from the second quarter, and October patient shipments reached the highest monthly level since launch, with the prescriber base now at about 1,300. Strip out the one-time settlement charge and the company generated USD 140.5 million of adjusted EBITDA, showing that the product is already highly profitable at current volumes. The settlement charge was known in substance after the October 13 agreement, so the quarter confirmed its size rather than surprising the market. Removing litigation risk also lowers the discount investors had applied to future Yutrepia cash flows.

The Settlement and Its Costs

Under the agreement, Liquidia pays United Therapeutics USD 175 million within 30 business days, followed by two instalments of USD 72.7 million due by January 31 and April 30, 2027, while USD 60.3 million went to other parties in October 2026. Cash of USD 396.1 million at the end of September, before those payments, plus the strong cash generation from Yutrepia, should cover the obligations without new financing. The settlement does carry a commercial cost. Liquidia will not appeal a Patent ruling covering pulmonary hypertension associated with interstitial lung disease, has asked the FDA to remove that indication from the Yutrepia label and has stopped promoting the product for it. That narrows the near-term market to pulmonary arterial hypertension, though that population alone has supported rapid growth so far. Management argued that certainty is worth more than the risk of further court battles.

Growth Beyond the Current Label

The company is also working to broaden the drug's use. Yutrepia received Fast Track Designation in September 2026 for Raynaud's phenomenon linked to systemic sclerosis, and the Phase 2 RE-WARM study has enrolled its first patient. Success there would open a new market outside lung disease. In the near term, investors in Liquidia (NASDAQ:LQDA) will track monthly shipment trends, the pace of new prescribers and whether payer coverage keeps expanding. The cash drain from settlement instalments ends in April 2027, after which more of the operating profit should flow through to the balance sheet. Competition in inhaled treprostinil remains intense, and United Therapeutics markets a rival product, so pricing and access will remain important.

Where Things Stand

Liquidia rose 7.37% on November 10, 2026 as Yutrepia sales of USD 222.7 million and adjusted EBITDA of USD 140.5 million outweighed a USD 389.7 million settlement charge. The deal with United Therapeutics removes six lawsuits at a cost of USD 380.7 million in net payments, and gives up the interstitial lung disease indication. Shipment growth and the new Raynaud's programme are the next drivers to watch.